Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLG802 Plus Temozolomide in Progressive Pediatric Brain Cancer
NCT07732413Phase 1Not yet recruiting
- Sponsor
- Lumos Pharma, Inc.
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nlg802 in brain cancer and spinal cancer, sponsored by Lumos Pharma, Inc. Primary endpoint: Maximum Tolerated Dose at 28 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
nlg802
03
Conditions
brain cancerspinal cancer
Beyond the preview
Go deeper on NCT07732413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07732413.